Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
05/2005
05/18/2005CN1616104A Transfusion medicine prepared from xylitol as istonic regulator and various injections separately and its preparing method
05/18/2005CN1616084A Botulinum toxin pharmaceutical compositions
05/18/2005CN1615995A Cyclodextrin super molecular composition of Chinese medicine giant knutweed rhizome and its preparing method
05/18/2005CN1615905A White arsenic local slow release chemical therapeutic medicine for treating malignant brain tumor
05/18/2005CN1615885A Method for preparing long acting progestational hormone injection embedded agent and use
05/18/2005CN1615868A Cyclic dextrin inclusion compound of mintpress hydrochloride and its preparing method
05/18/2005CN1615841A Taxinol-sodium alginate micro ball vascular embolism agent and its preparation
05/18/2005CN1615839A Utilization of dialkylfumarates
05/18/2005CN1615823A Nose spray agent
05/18/2005CN1615819A External use composition
05/18/2005CN1202162C Dissolving and filming method of egg shell membrane
05/18/2005CN1202130C Solid, stable and concentrated type ortho-silicis acid complex based on bio-absorption, and its prepn. method
05/18/2005CN1201822C Compositions comprising sympathomimetic amine salts unsuitable for illegal use
05/18/2005CN1201821C Stable complex of insoluble chemical compound
05/18/2005CN1201816C Pharmaceutical formulations for IGF/IGFBP
05/18/2005CN1201815C Stabilizer for recombinant alpha-interferon liquid
05/18/2005CN1201811C Chinese medicine composition for treating myopia and preparing method thereof
05/18/2005CN1201749C Vaginal delivery of bisphosphonates
05/18/2005CN1201748C Method for the production of polyvinylpyrrolidone-iodine in an aqueous solution
05/18/2005CN1201732C Oral pharmaceutical forms of administration with a delayed action
05/18/2005CN1201731C Medicine preparation and its use and the use of high grade primary alcohol mixture
05/18/2005CN1201729C Matrices formed of polymer and hydrophobic compounds for use in drug delivery
05/18/2005CN1201728C Incorporation of active substances in carrier matrixes
05/18/2005CN1201716C Cosmetic
05/17/2005US6894078 Alcohol based topical anesthetic formulation and method
05/17/2005US6894071 Medical compositions for intravesical treatment of bladder cancer
05/17/2005US6894027 Stimulation of bone growth with thrombin peptide derivatives
05/17/2005US6894025 Biologically active molecules having thiol moiety conjugated to polymers containing ethyl sulfone moiety
05/17/2005US6893665 Tetracycline derivatives that are not removed from the gastro-intestinal tract via absorption, therefore having minimal systemic exposure and accompanying side effects in cancer therapy
05/17/2005US6893662 Comprises methacrylic acid-methyl methacrylate copolymer layers for drug delivery to gastrointestinal tract
05/17/2005US6893659 Pharmaceutical composition for oral administration of a N-piperidino-3- pyrazolecarboxamide derivative, its salts and their solvates
05/17/2005US6893652 Comprises moxidectin, praziquantel, benzyl alcohol, ethanol, colloidal silicon dioxide, surfactant, and oil; veterinary medicine
05/17/2005US6893645 Process to make a sustained release formulation
05/17/2005US6893625 Mediating cytolysis; two light chains and two heavy chains; nonhuman variable region and human constant region; specifi-city for CD20 antigen bound by hybridoma HB9303 produced antibody
05/17/2005CA2486752A1 Process for the removal of porogens from temperature sensitive macroreticular polymers using steam at reduced pressure
05/17/2005CA2342130C Gel-based cosmetic composition
05/17/2005CA2234409C Transferrin receptor protein of moraxella
05/12/2005WO2005042741A2 METHODS AND COMPOSITIONS FOR TREATING 5alpha-REDUCTASE TYPE 1 AND TYPE 2 DEPENDENT CONDITIONS
05/12/2005WO2005042695A2 Lipoparticles comprising proteins, methods of making, and using the same
05/12/2005WO2005042620A1 Cationic polymers having degradable crosslinks
05/12/2005WO2005042619A1 Tri-block copolymers and a process for the preparation of the same
05/12/2005WO2005042600A2 High molecular weight polymers, devices and method for making and using same
05/12/2005WO2005042590A2 Cyclodextrin amphiphilic derivatives, method for preparing same and uses thereof
05/12/2005WO2005042588A1 Cellulose derivative
05/12/2005WO2005042584A2 Sulfoalkyl ether-alkyl ether cyclodextrin derivatives
05/12/2005WO2005042560A2 Non-viral delivery of compounds to mitochondria
05/12/2005WO2005042539A1 Tocopherol-modified therapeutic drug compounds
05/12/2005WO2005042142A2 Thermosensitive, biocompatible polymer carriers with a variable physical structure for treatment, diagnosis and analysis
05/12/2005WO2005042034A1 Peptides whose uptake by cells is controllable
05/12/2005WO2005042029A2 Psma formulations and uses thereof
05/12/2005WO2005042028A2 Il-13 conjugated to an immunogen and uses thereof
05/12/2005WO2005042027A2 Antagonists of the bradykinin b1 receptor
05/12/2005WO2005042026A1 Water-based composition undergoing reversible thermogelation
05/12/2005WO2005042025A1 Elutable surface coating
05/12/2005WO2005042024A1 Stable pharmaceutical composition comprising granulocyte-colony stimulating factor
05/12/2005WO2005042023A1 Composite material comprising a porous semiconductor impregnated with an organic substance
05/12/2005WO2005042016A2 Stabilised compositions
05/12/2005WO2005041980A1 Soft steroid compositions for use in dry powder inhalers
05/12/2005WO2005041967A1 Transdermal preparations and method for relieving side effects in pergolide therapy
05/12/2005WO2005041956A1 Pharmaceutical compositions based on idazoxan salt or one of the polymorphs thereof
05/12/2005WO2005041937A2 Controlled release sterile injectable aripiprazole formulation and method
05/12/2005WO2005041936A2 Methods of treatment of cancer using a composition comprising a cytotoxic drug and a porous carrier material
05/12/2005WO2005041933A1 Nanoparticles for drug delivery
05/12/2005WO2005041930A1 Monodispersed solid lipid particle compositions
05/12/2005WO2005041929A1 Pharmaceutical compositions with synchronized solubilizer release
05/12/2005WO2005041928A1 Compositions and dosage forms for ehnanced absorption of iron
05/12/2005WO2005041927A1 Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin
05/12/2005WO2005041926A1 Compositions and dosage forms for enhanced absorption of 3-amino-n-butyl-phosphinic acid
05/12/2005WO2005041925A2 Compositions and dosage forms for enhanced absorption
05/12/2005WO2005041924A2 Administration of levodopa and carbidopa
05/12/2005WO2005041923A1 Compositions and dosage forms for enhanced absorption of metformin
05/12/2005WO2005041882A2 Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs
05/12/2005WO2005041871A2 Apparatus and method for enhancing transdermal drug delivery
05/12/2005WO2005041865A2 Compounds and method for treating cancer
05/12/2005WO2005041859A2 Conjugates and compositions for cellular delivery.
05/12/2005WO2005041684A2 Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof
05/12/2005WO2005027859A3 Patch
05/12/2005WO2005025488A3 Methods for the controlled delivery of pharmacologically active compounds
05/12/2005WO2005007185A3 Formulation for a protein pharmaceutical without added human serum albumin (hsa)
05/12/2005WO2005004916A3 Modified calcium phosphate excipient
05/12/2005WO2004101776A3 Novel uses of ppar modulators and professional apcs manipulated by the same
05/12/2005WO2004041754A3 Calixarene-based guest-host assemblies for guest storage and transfer
05/12/2005WO2003070903A3 RNA INTERFERENCE MEDIATED INHIBITION OF GRB2-ASSOCIATED BINDING PROTEIN 2 (GAB2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
05/12/2005US20050101762 Cyclic peptide for use as tool in transmembrane transport; drug delivery
05/12/2005US20050101671 Compounds and compositions for delivering active agents
05/12/2005US20050101642 Niacinamide derivatives as inhibitor of poly(ADP-ribose)polymerase; ranitidine, cimetidine, famotidine, nizatidine as gastric acid secretion control; immunomodulation and suppression of hypersensitivity and inflammatory reaction; IgE mediated allergic reaction; no side effects; virtually non-toxic
05/12/2005US20050101635 Delivering to an external portion of the body passageway of a patient in need of a therapeutically effective amount of an antihistamine or decongestant to treat inflammatory diseases
05/12/2005US20050101611 Oral formulation comprising an inhibitor compound of the ileal bile transport and an hmg co-a reductase inhibitor
05/12/2005US20050101582 Compositions and methods for treating a posterior segment of an eye
05/12/2005US20050101562 Lipase inhibiting composition
05/12/2005US20050101557 Immunostimulatory nucleic acid molecules
05/12/2005US20050101554 Methods for treating and preventing infectious disease
05/12/2005US20050101552 Neurodegenerative disease; demyelination diseases; brain disorders; screening stem cells in brain; animal models; Alzheimer's, Parkinson's, Huntington's disease
05/12/2005US20050101546 Increased solubility flavanolignan preparations
05/12/2005US20050101533 Dried blood factor composition comprising trehalose
05/12/2005US20050101525 Method of complexing a nucleic acid with a lipid-conjugated polyamide
05/12/2005US20050101524 Using arsenic oxide, or complex thereof; angiogenesis inhibitors; anticarcinogenic agents; neurodegenerative agents; antiischemic agents
05/12/2005US20050101517 An oily solution of testosterone decanoate suitable for injections; male contracepti ves
05/12/2005US20050101020 Methods and products for delivering biological molecules to cells using multicomponent nanostructures
05/12/2005US20050100986 Compositions and methods for targeting a polypeptide to the central nervous system
1 ... 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 ... 1712